Heterocyclic aspartyl protease inhibitors

1 2 Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Zhu, Zhaoning, McKittrick, Brian, Sun, Zhong-Yue, Ye, Yuanzan C, Voigt, Johannes H, Strickland, Corey, Smith, Elizabeth M, Stamford, Andrew W, Greenlee, William J, Mazzola, Jr, Robert D, Caldwell, John P, Cumming, Jared N, Wang, Lingyan, Wu, Yusheng, Iserloh, Ulrich, Guo, Tao, Le, Thuy X. H, Saionz, Kurt W, Babu, Suresh D, Hunter, Rachael C, Morris, Michelle L, Gu, Huizhong, Qian, Gang, Tadesse, Dawit
Format: Patent
Sprache:eng
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:1 2 Disclosed are compounds of the formula I or a stereoisomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein Also disclosed is the method of inhibiting aspartyl protease, and in particular, the methods of treating cardiovascular diseases, cognitive and neurodegenerative diseases, and the methods of inhibiting of Human Immunodeficiency Virus, plasmepins, cathepsin D and protozoal enzymes.Also disclosed are methods of treating cognitive or neurodegenerative diseases using the compounds of formula I in combination with a cholinesterase inhibitor or a muscarinic magonist or mantagonist.